Lars Rebien Sorensen is to retire as CEO of Novo Nordisk by the end of this year, and will be replaced by Lars Fruergaard Jorgensen, currently the Danish company's head of c
Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio